News and Trends 27 Jun 2022
Eye inflammation leads to FDA partial clinical hold on Nuvation Bio solid tumor study
U.S. biopharma company Nuvation Bio Inc. says the Food and Drug Administration (FDA) has placed a partial clinical hold on the company’s phase 1 dose escalation study of NUV-422 in solid tumors, including high grade glioma, HR+/HER2- advanced breast cancer and metastatic castration resistant prostate cancer. The company’s Phase 1 trial began enrolling patients in […]